



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**Oversight Committee Meeting Minutes**

May 20, 2015

**1. Meeting Called to Order**

A quorum being present, Dr. Rice, Chair, called the Oversight Committee to order at 10:10 a.m.

**2. Roll Call /Excused Absences**

**Board Members Present:**

Angelos Angelou (arrived 10:25 a.m.)

Gerry Geistweidt

Pete Geren

Ned Holmes

Will Montgomery

Cynthia Mulrow, M.D. (arrived 10:18 a.m.)

Amy Mitchell

Bill Rice, M.D.

Craig Rosenfeld, M.D.

**3. Adoption of Minutes from the February 18 and April 20, 2015 meetings. (TAB 1)**

**MOTION:**

Dr. Rice called for a motion to approve the minutes of the February 18 and April 20, 2015, Oversight Committee meetings.

Motion made by Dr. Rosenfeld and seconded by Mr. Montgomery.

**MOTION CARRIED UNANIMOUSLY**

**4. Public Comments**

Dr. Rice noted no requests for comment were received.

## **5. Chief Executive Officer Report (TAB 2)**

Mr. Wayne Roberts, Chief Executive Officer, presented his report.

### **Update on Legislative Activities**

Legislation of Interest:

- Appropriations Bill: no difference in the House and Senate versions except our contract rider, which is not specific to CPRIT but the same contract rider as other agencies.
- Senate Bill 197 by Schwertner (requiring CPRIT to develop a self-sufficiency plan) is waiting to be heard on the House floor, where it is expected to pass as modified. The Senate is expected to concur.
- House Bill 1282 by Zerwas (requiring CPRIT to collaborate with the Department of State Health Services on a strategic plan designed to reduce HPV-related morbidity and mortality) has passed the House, moved to the Senate and been sent to committee.
- House Bill 1952 by Springer (ending the product development program) has been left pending in House committee.
- House Bill 4062 by Coleman (increasing the limit for prevention program awards) would increase prevention funding to 20 percent of budget; pending in committee.
- Senate Bill 20 by Nelson (relating to state agency contracting) is expected to pass and have a significant impact on all state agency contracting issues.

### **Update on CEO Activities**

- June 8, 2015, Mr. Roberts will participate in a panel at the Redefining Early State Investments Conference being held in Houston.

### **Report on Funds Available for Grant Awards in FY 2015**

Mr. Roberts noted that information on current available funds for grants is behind Tab 2 in the Oversight Committee's meeting book.

There was no further discussion nor questions for Mr. Roberts.

### **Personnel**

Mr. Roberts announced new personnel hired, transfers within the agency, and the Governor's appointment of Donald (Dee) Margo to replace outgoing Oversight Committee member Gerry Geistweidt.

**6. Compliance Investigation Pursuant to Health & Safety Code § 102.2631 (Agenda Item 20)**

Dr. Rice announced that Agenda Item 20 would now be taken up out of order. He called the meeting into closed session at 10:30 a.m., pursuant to Health & Safety Code Section 102.2631, and invited Mr. Roberts, Dr. Kripke and Ms. Doyle into the closed session.

Dr. Rice reconvened the open meeting at 11:13 a.m. and declared no further action was required on this item at this time.

**7. Chief Prevention and Communications Officer Report—Prevention Grant Recommendations (Tab 3)**

**Prevention Program Report**

Dr. Rebecca Garcia, Chief Prevention and Communications Officer, noted the Prevention Program update could be found behind Tab 3 in the meeting materials. Her report provided an overview of the following activities:

- FY 2015 Review Cycle 2
- FY 2016 Review Cycle 1
- Other Activities

**Grant Award Recommendations**

Dr. Garcia reviewed the FY 2015 Cycle 2 proposed grant awards slates.

- Evidence Based Program services - 4 projects totaling \$5,749,973
- Colorectal Cancer Coalition - 2 projects totaling \$7,388,774
- Continuation/Expansion for Evidence Based Cancer Prevention Services - 5 projects totaling \$7,480,666

Dr. Garcia noted that although the proposed slates would add 11 projects to the prevention portfolio, 16 projects will be closing by the time the 11 are awarded. Therefore the percentage of counties covered by projects serving them directly would remain the same at 89 percent.

Mr. Geren shared with the Oversight Committee the discussion in the Prevention Subcommittee that showed how these applications align with the program priorities even though they were submitted before the priorities were developed. He also noted the subcommittee has asked staff to explore how best to collect information on the services by county that projects provide.

In response to the Oversight Committee's question about RFA award amounts, Dr. Garcia responded that the maximum for the Evidence Based Services award is \$1.5 million. The Competitive Continuation maximum award is also \$1.5 million. The

Colorectal Cancer Coalition awards did not have a funding cap because projects can vary widely depending on the size of the geographic service area and number of people they will serve. She stated that while the PP150061 colorectal cancer project at \$4.8 million will cover the same number of counties as the PP150054 award at \$2.5 million, PP150061 proposes to serve more people.

### Prevention Grant Award Recommendations

<b>App ID</b>	<b>Mech.</b>	<b>Application Title</b>	<b>Organization</b>	<b>Recommended funding</b>
PP150061	EBP-CRC	The C-SPAN Coalition: Colorectal Screening and Patient Navigation	The University of Texas Southwestern Medical Center	\$ 4,800,000*
PP150079	EBP	STOP HCC –Evidence-Based Hepatocellular Cancer Prevention Targeting Hepatitis C Virus Infection	The University of Texas Health Science Center at San Antonio	\$ 1,488,294
PP150071	EBP	FluFIT on the Frontera: Increasing Colorectal Cancer Screening on the Texas-Mexico Border	Val Verde Regional Medical Center	\$ 1,500,000
PP150053	CCE-EBP	BSPAN3: Breast Screening and Patient Navigation for Rural and Underserved Women across North Texas	The University of Texas Southwestern Medical Center	\$ 1,499,993
PP150054 **	EBP-CRC	Alliance for Colorectal Cancer Testing (ACT) in Southeast Texas	The University of Texas M. D. Anderson Cancer Center	\$ 2,588,774
PP150077	EBP	Media-Rich Mobile Dissemination of a Dysphagia Prevention Program for Head and Neck Cancer Patients during Radiation	The University of Texas M. D. Anderson Cancer Center	\$ 1,263,342
PP150086	CCE-EBP	Access to Breast and Cervical Care for West Texas (West/Central Texas)(ABCC4WT)	Angelo State University	\$ 1,480,898
PP150080	CCE-EBP	Empower Her To Care Expansion: Increasing Access to Breast Cancer Screening and the Continuum of Care for Underserved Texas Women	The Rose	\$ 1,500,000

<b>App ID</b>	<b>Mech.</b>	<b>Application Title</b>	<b>Organization</b>	<b>Recommended funding</b>
PP150078	EBP	Cada Paso del Camino: Outreach, Education, Screening, Health Insurance Navigation, and Linkage to Treatment for Breast, Cervical, and Colorectal Cancers	MHP, Inc. Promoviendo Vidas Saludables	\$ 1,498,337
PP150064	CCE-EBP	University Health System Evidence-Based Colorectal Cancer Prevention Screening Program	University Health System	\$ 1,499,775
PP150089	CCE-EBP	Increasing Breast and Cervical Cancer Screening and Diagnostic Rates in Rural, Frontier, and Border Counties for Uninsured, Underserved Women	Texas AgriLife Extension Service	\$ 1,500,000

\* The Prevention Review Council (PRC) recommended reducing the grant to \$4,800,000 from the requested amount due to efficiencies to be achieved with their current colorectal cancer screening grant.

\*\* PRC recommends monitoring this grant closely to ensure navigation to follow-up and treatment is occurring. Per the RFA, access to follow-up and treatment must be ensured. The grantee should track all abnormal findings, providing outcomes in routine reports.

The PRC based their recommendations for the slate of FY15 Cycle 2 awards on several factors including geographic distribution and cancer type.

#### COMPLIANCE CERTIFICATION

Ms. Kristen Doyle, Interim Chief Compliance Officer, presented her report on the Prevention Program Awards review process and certified the recommended awards for Oversight Committee approval.

#### CONFLICT OF INTEREST NOTIFICATIONS – Prevention Grant Awards

Dr. Rice reported Ms. Mitchell had conflicts with applications submitted by the following institutions:

- University Health System
- The University of Texas Health Science Center at San Antonio
- The University of Texas M.D. Anderson Cancer Center
- The University of Texas Southwestern Medical Center
- Texas Agrilife Extension Service
- Val Verde Regional Medical Center
- Angelo State University

In accordance with CPRIT's rules, Dr. Rice stated Ms. Mitchell was recused from the discussion or action on these applications.

Additionally, Dr. Rice reported that Dr. Mulrow reported a conflict with PP150079 and was recused from the discussion or action on this application.

**MOTION:**

Dr. Rice entertained a motion to approve the PIC's recommendations for Evidence Based Cancer Prevention grant awards for applications submitted by:

- The University of Texas M.D. Anderson Cancer Center
- Val Verde Regional Medical Center

Motion was made by Mr. Holmes and seconded by Mr. Montgomery.

**MOTION CARRIED UNANIMOUSLY**

Dr. Rice noted for the record that Ms. Mitchell abstained from voting.

**MOTION:**

Dr. Rice entertained a motion to approve the PIC's recommendation for Evidence Based Cancer Prevention grant awards for the applications submitted by:

- The University of Texas Health Science Center at San Antonio

Motion was made by Mr. Geistweidt and seconded by Mr. Holmes.

**MOTION CARRIED UNANIMOUSLY**

Dr. Rice noted for the record that Ms. Mitchell and Dr. Mulrow abstained from voting.

**MOTION:**

Dr. Rice entertained a motion to approve the PIC's recommendation for Evidence Based Cancer Prevention grant awards for the applications submitted by:

- MHP, Inc. Promoviendo Vidas Saludables

Motion was made by Mr. Geistweidt and seconded by Mr. Holmes.

**MOTION CARRIED UNANIMOUSLY**

**MOTION:**

Dr. Rice entertained a motion to approve the PIC's recommendations for Colorectal Cancer Prevention Coalition grant awards for applications submitted by:

- The University of Texas Southwestern Medical Center
- The University of Texas M.D. Anderson Cancer Center

Motion was made by Dr. Rosenfeld and seconded by Mr. Holmes.

**MOTION CARRIED UNANIMOUSLY**

Dr. Rice noted for the record that Ms. Mitchell abstained from voting.

**MOTION:**

Dr. Rice entertained a motion to approve the PIC's recommendations for Competitive Continuation and Expansion grant awards for applications submitted by:

- The University of Texas Southwestern Medical Center
- University Health System
- Texas Agrilife Extension Service
- Angelo State University

Motion was made by Mr. Geren and seconded by Mr. Geistweidt.

**MOTION CARRIED UNANIMOUSLY**

Dr. Rice noted for the record that Ms. Mitchell abstained from voting.

**MOTION:**

Dr. Rice entertained a motion to approve the PIC's recommendation for Competitive Continuation and Expansion grant awards for the applications submitted by:

- The Rose

Motion was made by Mr. Montgomery and seconded by Mr. Geistweidt.

**MOTION CARRIED UNANIMOUSLY**

**MOTION:**

Having approved the PIC recommendations for the Prevention grant awards, Dr. Rice entertained a motion to delegate contract negotiation authority to the Chief Executive Officer and CPRIT staff and to authorize the Chief Executive Officer to sign the contracts on behalf of the Institute.

Motion was made by Mr. Holmes and seconded by Mr. Montgomery.

**MOTION CARRIED UNANIMOUSLY**

**8. Chief Scientific Officer Report (Tab 4)**

**Academic Research Program Report**

Dr. Kripke gave an overview of the recommendations being made (see memo behind Tab 4 in the meeting materials), stating details of the proposed awards were behind the Academic Research tab in the meeting materials handout titled "Proposed Grant Awards." Dr. Kripke's report including the following:

- Research Applications 15.2 Cycle
- Research Applications 16.1 Cycle
- Research Applications 16.2 Cycle
- Recruitment Applications
- Research Subcommittee Activities
- University Advisory Committee Update

- Advisory Committee on Childhood Cancers Update

In response to an Oversight Committee (OC) member question about the expertise of the current panel to review computational biology applications, Dr. Kripke stated that some of the current panel members have the expertise to review ETRA applications and more will be recruited as needed. Responding to another OC member question on Training RFA's, she stated we have special instructions to promote diversity.

When asked by an OC member about the rules for resubmission of grants, Dr. Kripke said grantees could resubmit once.

Responding to an OC member question about core facility grants, Dr. Kripke said that the grants were limited to academic institutions and that making those grants available to for-profit institutions would be complicated and have legal implications.

When questioned by an OC member on whether the length of time to work through the application and contracting process is causing grantees to decline CPRIT recruitment awards, Dr. Kripke said she believes that when grants are declined, it is usually because the applicants are highly sought after and have multiple offers from other institutions, not because of our process. Our success rate for recruiting applicants that have been approved for a recruitment award is 70-80%, which is quite high, compared to candidates recruited to academic institutions without CPRIT awards.

**Grant Award Recommendations**

**Academic Research Grant Award Recommendations**

<b>App ID</b>	<b>Mechanism</b>	<b>Organization</b>	<b>Application Title</b>	<b>Budget</b>
RP150587	MIRA	Baylor College of Medicine	The Texas Hepatocellular Carcinoma Consortium (THCCC)	\$9,771,157
RP150611	CFSA	The Methodist Hospital Research Institute	CPRIT Core for RNA Therapeutics and Research	\$4,845,868
RP150535	CFSA	The University of Texas M. D. Anderson Cancer Center	Precision Oncology Decision Support Core	\$5,999,996
RP150573	HIHRRRA	The University of Texas Southwestern Medical Center	Dynamin GTPase: A novel pro-apoptotic cancer therapeutic target	\$200,000
RP150632	HIHRRRA	The University of Texas Southwestern Medical Center	Acetate may be a key substrate driving growth in early stage breast cancer in patients	\$200,000
RP150600	CFSA	The University of Texas Health Science Center at San Antonio	The Single-Cell Biopsy and Characterization Core (SBCC) at The University of Texas Health Science at San Antonio	\$3,277,895
RP150551	CFSA	The University of Texas Health Science Center at Houston	Therapeutic Monoclonal Antibody Lead Optimization and Development Core	\$5,277,338



<b>App ID</b>	<b>Mechanism</b>	<b>Organization</b>	<b>Application Title</b>	<b>Budget</b>
RP150640	HIHRRA	The University of Texas Health Science Center at Houston	Drug Conjugates of anti-LGR5 Antibodies as Novel Therapeutics for Destroying Cancer Stem Cells	\$200,000
RP150676	HIHRRA	The University of Texas Southwestern Medical Center	Identification of Novel Melanoma Metastasis Driver Genes through Transposon-Mediated Mutagenesis	\$200,000
RP150637	HIHRRA	Texas A&M University System Health Science Center	Efficient Production of iPSC-Derived Mesenchymal Stem Cells to Kill Cancers by Bystander Effects from Suicide Genes	\$200,000
RP150648*	MIRA	Baylor College of Medicine	GATA2 and steroid receptor coactivator-2 cooperate with androgen receptor in prostate cancer progression and androgen resistance	\$6,151,179
RP150703	HIHRRA	Texas A&M University System Health Science Center	Metabolomic Salivary Biomarkers for Oral Cancer Detection	\$199,999
RP150596	CFSA	The University of Texas Southwestern Medical Center	Bioinformatics Core Facility at UT Southwestern Medical Center	\$5,593,882
RP150720	HIHRRA	Texas Tech University	Integrated on-chip networks for investigating exosome-mediated drug expulsion	\$200,000
RP150559	HIHRRA	Texas A&M University	Small Molecules to Perturb A Novel PPI Target For Chemotherapy	\$200,000
RP150656	HIHRRA	Texas Tech University Health Sciences Center	Engineered Bone Targeting Nanomedicine for Treatment of Bone Metastases from Breast Cancer	\$199,970
RP150578	CFSA	Texas A&M University System Health Science Center	The Combinatorial Drug Discovery Program (CDDP)	\$5,954,596
RP150701	HIHRRA	Rice University	Non-invasive Colonoscopy by Molecular Imaging of Mucin Targeted Hyperpolarized Silicon Nanoparticles	\$200,000
RP150638	HIHRRA	Baylor Research Institute	Elevated D-2-hydroxyglutarate precedes and promotes tumor progression in inflammatory bowel diseases	\$200,000
RP150590	HIHRRA	The University of Texas Southwestern Medical Center	Identifying Inhibitors of Ascl1 to Block Growth of Malignant Neuroendocrine and Neural Tumors	\$200,000

<b>App ID</b>	<b>Mechanism</b>	<b>Organization</b>	<b>Application Title</b>	<b>Budget</b>
RP150713	HIHRRRA	The University of Texas at Dallas	Identification of Therapeutic Targets on Breast Cancer Stem Cells	\$194,543
RP150696	HIHRRRA	The University of Texas Health Science Center at San Antonio	Inhibition of Breast Cancer Metastasis to the Bone by microRNA Transmission through Gap Junctions	\$200,000
RP150711	HIHRRRA	The University of Texas at Arlington	Biomechanical profiling of migrating brain cancer genotypes in tightly-confined space for drug screening	\$199,998
RP150574	HIHRRRA	The University of Texas Health Science Center at San Antonio	Turning on a Novel Tumor-Inhibiting Switch for Colorectal Cancer	\$200,000

### **Academic Research Recruitment Grant Award Recommendations**

<b>App ID</b>	<b>Mechanism</b>	<b>Organization</b>	<b>Candidate</b>	<b>Budget Requested</b>
RR150060**	RFT	The University of Texas Southwestern Medical Center	Dr. Randal Halfmann	\$2,000,000
RR150062	RFT	The University of Texas Southwestern Medical Center	Dr. Shixin Liu	\$2,000,000
RR150058	RFT	The University of Texas Southwestern Medical Center	Dr. Andreas Doncic	\$2,000,000
RR150054	REI	The University of Texas M. D. Anderson Cancer Center	Dr. Hongtu Zhu	\$4,000,000*
RR150059	RFT	The University of Texas Southwestern Medical Center	Dr. Maralice Conacci-Sorrell	\$2,000,000
RR150044	RFT	Rice University	Dr. Natalia Kirienko	\$2,000,000

RFT = Recruitment of First-Time, Tenure-Track Faculty Members

REI = Recruitment of Established Investigators

\*The award amount for this REI candidate was reduced from \$6M to \$4M at the recommendation of the SRC.

\*\*RR150060 was withdrawn by the applicant after the meeting of the SRC but before the PIC meeting.

### **COMPLIANCE CERTIFICATION**

Ms. Kristen Doyle, Interim Chief Compliance Officer, presented her report on the Academic Research Program Awards review process and certified the recommended awards for Oversight Committee approval.

## CONFLICT OF INTEREST NOTIFICATIONS

Dr. Rice noted for the record that Ms. Mitchell reported conflicts with applications submitted by the following institutions:

- Baylor College of Medicine
- Baylor Research Institute
- Methodist Hospital Research Institute
- Rice University
- The University of Texas at Arlington
- The University of Texas at Dallas
- The University of Texas Health Science Center at Houston
- The University of Texas Health Science Center at San Antonio
- The University of Texas M.D. Anderson Cancer Center
- The University of Texas Southwestern Medical Center
- Texas Tech University
- Texas Tech University Health Sciences Center
- Texas A&M University
- Texas A&M University Health Science Center

Dr. Rice stated that in accordance with CPRIT's rules, Ms. Mitchell was recused from the discussion or action on these applications.

No other conflict of interest declarations for Oversight Committee members were reported.

### **MOTION:**

Dr. Rice entertained a motion to approve each of the PIC's recommendations for Core Facility Support grant awards for applications submitted by:

- Methodist Hospital Research Institute
- The University of Texas Health Science Center at Houston
- The University of Texas Health Science Center at San Antonio
- The University of Texas M.D. Anderson Cancer Center
- The University of Texas Southwestern Medical Center
- Texas A&M University Health Science Center

Motion was made by Mr. Geistweidt and seconded by Mr. Angelou.

**MOTION CARRIED UNANIMOUSLY**

Dr. Rice noted for the record that Ms. Mitchell abstained from voting.

### **MOTION:**

Dr. Rice entertained a motion to approve the PIC's recommendation for the High Impact High Risk Awards submitted by:

- Baylor Research Institute

- Methodist Hospital Research Institute
- Rice University
- The University of Texas at Arlington
- The University of Texas at Dallas
- The University of Texas Health Science Center at Houston
- The University of Texas Health Science Center at San Antonio
- The University of Texas M.D. Anderson Cancer Center
- The University of Texas Southwestern Medical Center
- Texas Tech University
- Texas Tech University Health Sciences Center
- Texas A&M University
- Texas A&M University Health Science Center

Motion by Mr. Geistweidt and seconded by Dr. Rosenfeld.

**MOTION CARRIED UNANIMOUSLY**

Dr. Rice noted for the record that Ms. Mitchell abstained from voting.

**MOTION:**

Dr. Rice entertained a motion to approve the PIC's recommendation for the two Multi-Investigator Research Awards submitted by:

- Baylor College of Medicine

Motion was made by Mr. Holmes and seconded by Dr. Rosenfeld.

**MOTION CARRIED UNANIMOUSLY**

Dr. Rice noted for the record that Ms. Mitchell abstained from voting.

**MOTION:**

Dr. Rice entertained a motion to approve the PIC's recommendation for the First Time Tenure Track Recruitment Awards submitted by:

- The University of Texas Southwestern Medical Center
- Rice University

Motion was made by Mr. Holmes and seconded by Dr. Mulrow.

**MOTION CARRIED UNANIMOUSLY**

Dr. Rice noted for the record that Ms. Mitchell abstained from voting.

**MOTION:**

Dr. Rice entertained a motion to approve the PIC's recommendation for the Established Investigator Recruitment Awards submitted by:

- The University of Texas M.D. Anderson Cancer Center

Motion was made by Mr. Holmes and seconded by Mr. Geren.

**MOTION CARRIED UNANIMOUSLY**

Dr. Rice noted for the record that Ms. Mitchell abstained from voting.

**MOTION:**

The PIC recommendations for the Academic Research and Recruitment grant awards having been approved, Dr. Rice entertained a motion to delegate contract negotiation authority to the Chief Executive Officer and CPRIT staff and to authorize the Chief Executive Officer to sign the contracts on behalf of the Institute

Motion was made by Mr. Montgomery and seconded by Dr. Mulrow.

**MOTION CARRIED UNANIMOUSLY**

**9. Chief Product Development Officer Report (TAB 5)**

**Product Development Research Program Report**

Dr. Goodman, Chief Product Development Officer, presented updates on the following program items:

- Mechanism of Support and Program Objectives
- Established Company Awards
- Summary of the Product Development Research awards approved by the Program Integration Committee (PIC).

Dr. Goodman reported that staff are in the process of visiting every awardee to keep abreast of compliance, and it is anticipated that staff will visit every grantee at least yearly.

Dr. Goodman noted that three awards were recommended to the PIC by the Product Development Review Council (PDRC) but that the PIC was forwarding only two recommendations to the Oversight Committee for approval. Details of the proposed awards were provided in the meeting materials.

In response to an OC member's question about the PDRC recommendation the PIC rejected, Mr. Roberts noted that he had dissented from the PIC's majority decision to reject the PDRC's recommendation. Although Mr. Roberts initially took the minority position recommending that the Oversight Committee approve an award to the company rejected by the PIC, he reports that he withdrew that recommendation prior to the Oversight Committee meeting. Noting that the minority recommendation was not before the Oversight Committee for consideration, Dr. Rice stated that the meeting discussion would focus on the two grants recommended by the PIC.

An OC member asked what would happen if a company left Texas after having been awarded a grant: would the money be returned or would CPRIT continue to have an interest in the company. Dr. Goodman responded that if they leave within three years,

the money would have to be refunded by the company but the revenue sharing terms would still be in effect.

The OC members discussed among themselves and the staff the definition of abandonment.

**Grant Award Recommendations**

<b>Application ID</b>	<b>Company Name</b>	<b>Award Type</b>	<b>Project</b>	<b>Requested Budget</b>
DP150019	Vermillion, Inc.	Established Company	Development and Validation of a Second-Generation Multivariate Test for Use in Assessing Risk of Ovarian Mass Malignancy	\$7,533,011
DP150005	Rosellini Scientific, Inc.	New Company	Wireless Neuro-modulation Treatment for Bladder Dysfunction Secondary to Cancer	\$967,000

**COMPLIANCE CERTIFICATION**

Ms. Kristen Doyle, Interim Chief Compliance Officer, presented her report on the Product Development Research Program Awards review process and certified the recommended awards for Oversight Committee approval.

**CONFLICT OF INTEREST NOTIFICATIONS – Product Development Research Grant Awards**

Dr. Rice noted for the record that Ms. Mitchell reported a conflict with the application submitted by Vermillion, Inc.

**MOTION:**

Dr. Rice entertained a motion to approve the PIC’s recommendation for the Established Company Product Development Research Award and award amount, as recommended by the PIC.

Motion was made by Mr. Montgomery and seconded by Dr. Rosenfeld.

**MOTION CARRIED UNANIMOUSLY**

Dr. Rice noted for the record that Ms. Mitchell abstained from voting.

**MOTION:**

Dr. Rice entertained a motion to approve the PIC’s recommendation for the New Company Product Development Research Award and award amount, as recommended by the PIC.

Motion was made by Mr. Montgomery and seconded by Dr. Rosenfeld.

**MOTION CARRIED UNANIMOUSLY**

**MOTION:**

Having approved the PIC recommendations for the two Product Development Research Awards, Dr. Rice entertained a motion to delegate contract negotiation authority to the Chief Executive Officer and CPRIT staff and to authorize the Chief Executive Officer to sign the contracts on behalf of the Institute.

Motion was made by Mr. Geistweidt and seconded by Mr. Geren.

**MOTION CARRIED UNANIMOUSLY**

**MOTION:**

Dr. Rice entertained a motion to authorize CPRIT to disburse grant funds via advance payments to the two Product Development Research Awards approved, pursuant to the General Appropriations Act, Article IX, Section 4.03(a).

Motion was made by Mr. Montgomery and seconded by Dr. Rosenfeld.

**MOTION CARRIED UNANIMOUSLY**

**10. FY 2016 Bond Issuance Resolution (TAB 6)**

Ms. Heidi McConnell, Chief Operating Officer presented the staff recommendation to approve the FY 2016 request for financing bond resolution to the Texas Public Finance Authority to issue debt on behalf of CPRIT in the amount of \$300 million in bond proceeds for agency operations and grant awards.

Mr. Angelou, Chair of the Audit Subcommittee, presented the subcommittee's recommendation of approval.

**MOTION:**

Dr. Rice entertained a motion to approve CPRIT's resolution authorizing a request for financing to the Texas Public Finance Authority.

Motion was made by Mr. Holmes and seconded by Ms. Mitchell.

**MOTION CARRIED UNANIMOUSLY**

**11. FY 2016 Contract Renewal – SRA International (TAB 7)**

Ms. McConnell presented staff recommendations to exercise the 12-month renewal option with SRA International for the Pre-and Post-Award Grants Management Support Services at an estimated cost of \$9.6 million in FY 2016.

Mr. Angelou presented the Audit Subcommittee recommendation to renew the SRA contract.

In response to OC member questions, Mr. Roberts stated that the Governor's request that state agencies begin implementing the provisions of Senate Bill 20 (regarding contracting reform) does apply to this request. He also stated that this contract renewal will need to be approved by the Legislative Budget Board, which is currently extremely busy in the closing weeks of the session. Given the possibility that this approval process is slowed down, there may be a period of time when the agency is without this service. The contract renewal would be effective September 1, 2015.

**MOTION:**

Dr. Rice entertained a motion to approve a contract renewal with SRA International for FY 2016.

Motion was made by Mr. Montgomery and seconded by Dr. Rosenfeld.

**MOTION CARRIED UNANIMOUSLY**

**12. Final Order Approving Amendments to 25 T.A.C. Chapter 703 (TAB 8)**

Ms. Doyle presented the proposed rule change. She stated the rule change was provisionally approved at the February 2015 meeting and published in the Texas Register for comments. Staff is now requesting final approval.

Dr. Rice referred to a memo from the Board Governance Subcommittee Chair recommending approval of these rule changes.

**MOTION:**

Dr. Rice entertained a motion to approve the final orders adopting CPRIT's rule changes and to direct staff to file the orders with the Secretary of State.

Motion was made by Mr. Holmes and seconded by Dr. Mulrow.

**MOTION CARRIED UNANIMOUSLY**

**13. Proposed Amendment to 25 T.A.C. Chapter 703 and Authorization to Publish in the Texas Register (TAB 9)**

Ms. Doyle presented the proposed Amendment to T.A.C. Chapter 703.

Dr. Rice referred to a memo from the Board Governance Subcommittee Chair recommending for approval of the proposed changes.

**MOTION:**

Dr. Rice entertained a motion to instruct staff to publish the proposed rule amendments to Chapter 703 in the *Texas Register* in accordance with the requirements of the Administrative Procedure Act.

Motion was made by Ms. Mitchell and seconded by Mr. Geistweidt.



**MOTION CARRIED UNANIMOUSLY**

**14. Board Governance – Upcoming Officer Elections and Subcommittee Assignments (TAB 10)**

Dr. Rice started discussion on a memo from the Chair of the Board Governance Subcommittee recommending a process to recommend officer candidates. The process would be led by the outgoing Chair and the Nominations Subcommittee, which would put together a slate of nominees. Mr. Roberts and Ms. Doyle presented recommended changes to the charter of the Nominations Subcommittee and also to the Oversight Committee bylaws.

**MOTION:**

Dr. Rice entertained a motion to approve the proposed process for officer elections as reflected in the amendments to the Oversight Committee Bylaws and Nominations Subcommittee charter.

Motion was made by Dr. Rosenfeld and seconded by Mr. Montgomery.

**MOTION CARRIED UNANIMOUSLY**

**15. Interim Chief Compliance Officer Report (TAB 11)**

Ms. Kristen Doyle, Interim Chief Compliance Officer, discussed the following items included in her memo:

- Submission Status of Required Grant Recipient Reports
- CPRIT's Grants Reports Reconciliation Project
- Compliance Program Activities
  - Training
  - FSR Reviews
  - Desk Reviews
  - On-site Visits
  - Reporting

Ms. Doyle also reported that CohnReznik began providing compliance program support on April 30, 2015, and the new agency's new Chief Compliance Officer, Mr. Vince Burgess, will begin work June 15, 2015.

**16. Chief Operating Officer Report (TAB 12)**

Ms. Heidi McConnell, Chief Operating Officer, provided the Chief Operating Officer Report (behind Tab 12 in the meeting materials) which included the following topics:

- FY 2015, Quarter 2 Operating Budget
- FY 2015, Quarter 2 Performance Measures
- Debt Issuance History

**17. Chief Prevention and Communications Officer Report – Communications Report (TAB 13)**

Dr. Rebecca Garcia, Chief Prevention and Communications Officer, stated her Communications Report could be found behind Tab 13 in the meeting materials. She discussed the following items:

- Earned Media Report
- CPRIT 2015 Conference
- CPRIT Messages and Accomplishments
- PBS Cancer Documentary Screening
- Patient Videos
- Social Media

**18. FY 2016 Program Priorities Process (TAB 14)**

Mr. Roberts stated his memo regarding FY 2016 Program Priorities Discussion could be found behind Tab 14. Discussion of the program priorities was postponed until the August 19, 2015, meeting.

**19. Requests for Applications (TAB 15)**

Mr. Roberts stated the Oversight Committee had requested at its April 20, 2015, meeting that staff provide a history of the release of Requests for Applications (RFAs) for each program mechanism and to identify future releases in FY 2016. He noted that information is provided behind Tab 15 of the meeting materials to be used in the Program Priorities discussion.

**20. Personnel – Chief Scientific Officer, Chief Compliance Officer (TAB 16)**

Mr. Roberts outlined the current timeline, process and interview committee for the national search for a new chief scientific officer to replace Dr. Kripke, who is retiring on or about August 31, 2015.

There was no discussion of the Chief Compliance Officer position.

**21. Subcommittee Business**

This agenda item was not taken up.

**22. Consultation with General Counsel**

This agenda item was not taken up.

**23. Future Meeting Dates and Agenda Items**

Dr. Rice stated that the next regular Oversight Committee meeting is scheduled for August 19, 2015. CPRIT staff will circulate a tentative agenda prior to the meeting.

Dr. Rice also noted the possible need for a September meeting. After discussion, the Oversight Committee members decided on a date of Thursday, September 10, 2015, should that meeting be necessary.


**24. Adjourn**

**MOTION:**


There being no further business, Dr. Rice moved to adjourn the meeting at 2:00 p.m.

Motion was seconded by Mr. Montgomery.

**MOTION CARRIED UNANIMOUSLY**



Signature



Date



CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**Conflict of Interest Disclosure – Oversight Committee Members  
For Applications Recommended for Consideration at May 20, 2015, Open Meeting**

**Conflict of Interest Disclosure - Amy Mitchell**

Academic Research (24)


RP150535, RP150551, RP150559, RP150573, RP150574, RP150578, RP150587, RP150590,  
RP150596, RP150600, RP150611, RP150632, RP150637, RP150638, RP150640, RP150648,  
RP150656, RP150676, RP150696, RP150701, RP150703, RP150711, RP150713, RP150720,  
RR150044, RR150054, RR150058, RR150059, RR150062

**Conflict of Interest Disclosure – Cynthia Mulrow**

Prevention (1)

PP150079

By my signature, this list of reported conflicts of interest shall be included as the official record of conflicts of interest reported by Oversight Committee members for grant award recommendations considered at the November 19, 2014, Oversight Committee meeting.

  
\_\_\_\_\_  
Dr. William Rice, Presiding Officer, Oversight Committee

5-20-15  
\_\_\_\_\_  
Date

  
\_\_\_\_\_  
Amy Mitchell, Secretary, Oversight Committee

5/20/15  
\_\_\_\_\_  
Date



W  
Ann

---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

May 6, 2015

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendations for funding 42 grant applications totaling \$91,185,945 in grants. The PIC recommendations for 29 academic research grant awards, 2 product development research awards, and 11 prevention awards are attached. The program officers have prepared overviews of the academic research, product development research, and prevention program slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary of the recommended proposals with enough detail that you should be able to understand the substance of the proposal and the reasons endorsing grant funding. All of the information reviewed by the Review Councils is available by clicking on the appropriate link in the portal. This information includes the full application, peer reviewer critiques, budget/scope change recommendations (if applicable) and the CEO affidavit for each proposal.

*For the first time the PIC has a split decision on one product development research award recommendation. A majority of the PIC voted not to recommend the award. I disagreed with that decision and have prepared a minority recommendation following the process called for by CPRIT's administrative rules. My minority recommendation as well as the majority's reasoning for not recommending the grant application are on the portal.*

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Kristen Doyle, CPRIT's Interim Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on Wednesday, May 20, 2015. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information. This is particularly important because some recommendations are for publicly traded companies, which implicates state and federal securities law as described by the memorandum prepared by Ms. Doyle that is on the portal.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas. Thank you for being part of this endeavor.

Sincerely,  
Wayne R. Roberts  
Chief Executive Officer

## Academic Research Award Recommendations –

The PIC unanimously recommends approval of 29 academic research grant proposals totaling \$62,066,521. The recommended grant proposals were submitted in response to one of five grant mechanisms: Core Facilities Support Awards, Multi-Investigator Research Awards, High-Impact/High-Risk Research Awards; Recruitment of First-Time, Tenure-Track Faculty; and Recruitment of Established Investigators. The PIC followed the recommendations made by the Scientific Review Council (SRC). The SRC provided the prioritized list of recommendations for the Recruitment awards to the presiding officers on April 22, 2015.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these academic research proposals met the following CPRIT funding priorities:

- could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;
- strengthen and enhance fundamental science in cancer research;
- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
- address federal or other major research sponsors' priorities in emerging scientific or technology fields in the area of cancer prevention or cures for cancer;
- are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state (the PIC chose this factor for Multi-Investigator Research Awards and High-Impact, High-Risk Research Awards);
- have a demonstrable economic development benefit to this state;
- enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources; and
- address the goals of the Texas Cancer Plan.

### Academic Research Grant Award Recommendations

Rank	App ID	Mechanism	Organization	Application Title	Budget	Score
1	RP150587	MIRA	Baylor College of Medicine	The Texas Hepatocellular Carcinoma Consortium (THCCC)	\$9,771,157	1.9
2	RP150611	CFSA	The Methodist Hospital Research Institute	CPRIT Core for RNA Therapeutics and Research	\$4,845,868	2.0
3	RP150535	CFSA	The University of Texas M. D. Anderson Cancer Center	Precision Oncology Decision Support Core	\$5,999,996	2.0

Rank	App ID	Mechanism	Organization	Application Title	Budget	Score
4	RP150573	HIHRRA	The University of Texas Southwestern Medical Center	Dynamin GTPase: A novel pro-apoptotic cancer therapeutic target	\$200,000	2.0
5	RP150632	HIHRRA	The University of Texas Southwestern Medical Center	Acetate may be a key substrate driving growth in early stage breast cancer in patients	\$200,000	2.0
6	RP150600	CFSA	The University of Texas Health Science Center at San Antonio	The Single-Cell Biopsy and Characterization Core (SBCC) at The University of Texas Health Science at San Antonio	\$3,277,895	2.1
7	RP150551	CFSA	The University of Texas Health Science Center at Houston	Therapeutic Monoclonal Antibody Lead Optimization and Development Core	\$5,277,338	2.1
8	RP150640	HIHRRA	The University of Texas Health Science Center at Houston	Drug Conjugates of anti-LGR5 Antibodies as Novel Therapeutics for Destroying Cancer Stem Cells	\$200,000	2.1
9	RP150676	HIHRRA	The University of Texas Southwestern Medical Center	Identification of Novel Melanoma Metastasis Driver Genes through Transposon-Mediated Mutagenesis	\$200,000	2.1
10	RP150637	HIHRRA	Texas A&M University System Health Science Center	Efficient Production of iPSC-Derived Mesenchymal Stem Cells to Kill Cancers by Bystander Effects from Suicide Genes	\$200,000	2.2
11	RP150648*	MIRA	Baylor College of Medicine	GATA2 and steroid receptor coactivator-2 cooperate with androgen receptor in prostate cancer progression and androgen resistance	\$6,151,179	2.3
12	RP150703	HIHRRA	Texas A&M University System Health Science Center	Metabolomic Salivary Biomarkers for Oral Cancer Detection	\$199,999	2.6
13	RP150596	CFSA	The University of Texas Southwestern Medical Center	Bioinformatics Core Facility at UT Southwestern Medical Center	\$5,593,882	2.7

Rank	App ID	Mechanism	Organization	Application Title	Budget	Score
14	RP150720	HIHRRRA	Texas Tech University	Integrated on-chip networks for investigating exosome-mediated drug expulsion	\$200,000	2.7
15	RP150559	HIHRRRA	Texas A&M University	Small Molecules to Perturb A Novel PPI Target For Chemotherapy	\$200,000	2.7
16	RP150656	HIHRRRA	Texas Tech University Health Sciences Center	Engineered Bone Targeting Nanomedicine for Treatment of Bone Metastases from Breast Cancer	\$199,970	2.8
17	RP150578	CFSA	Texas A&M University System Health Science Center	The Combinatorial Drug Discovery Program (CDDP)	\$5,954,596	3.0
18	RP150701	HIHRRRA	Rice University	Non-invasive Colonoscopy by Molecular Imaging of Mucin Targeted Hyperpolarized Silicon Nanoparticles	\$200,000	3.0
19	RP150638	HIHRRRA	Baylor Research Institute	Elevated D-2-hydroxyglutarate precedes and promotes tumor progression in inflammatory bowel diseases	\$200,000	3.1
20	RP150590	HIHRRRA	The University of Texas Southwestern Medical Center	Identifying Inhibitors of Ascl1 to Block Growth of Malignant Neuroendocrine and Neural Tumors	\$200,000	3.2
21	RP150713	HIHRRRA	The University of Texas at Dallas	Identification of Therapeutic Targets on Breast Cancer Stem Cells	\$194,543	3.3
22	RP150696	HIHRRRA	The University of Texas Health Science Center at San Antonio	Inhibition of Breast Cancer Metastasis to the Bone by microRNA Transmission through Gap Junctions	\$200,000	3.4
23	RP150711	HIHRRRA	The University of Texas at Arlington	Biomechanical profiling of migrating brain cancer genotypes in tightly-confined space for drug screening	\$199,998	3.4



Rank	App ID	Mechanism	Organization	Application Title	Budget	Score
24	RP150574	HIHRRRA	The University of Texas Health Science Center at San Antonio	Turning on a Novel Tumor-Inhibiting Switch for Colorectal Cancer	\$200,000	3.4

\*RP150648 - The peer review panel recommended the removal of a MIRA project. The budget was reduced based on the deletion of that project plus a 20% reduction of the remaining budget.

### Academic Research Recruitment Grant Award Recommendations

Rank	App ID	Mechanism	Organization	Candidate	Budget Requested	Overall Score
1	RR150060**	RFT	The University of Texas Southwestern Medical Center	Dr. Randal Halfmann	\$2,000,000	1.0
2	RR150062	RFT	The University of Texas Southwestern Medical Center	Dr. Shixin Liu	\$2,000,000	1.0
3	RR150058	RFT	The University of Texas Southwestern Medical Center	Dr. Andreas Doncic	\$2,000,000	1.3
4	RR150054	REI	The University of Texas M. D. Anderson Cancer Center	Dr. Hongtu Zhu	\$4,000,000*	1.8
5	RR150059	RFT	The University of Texas Southwestern Medical Center	Dr. Maralice Conacci-Sorrell	\$2,000,000	2.0
6	RR150044	RFT	Rice University	Dr. Natalia Kirienko	\$2,000,000	2.2

RFT = Recruitment of First-Time, Tenure-Track Faculty Members

REI = Recruitment of Established Investigators

\*The award amount for this REI candidate was reduced from \$6M to \$4M at the recommendation of the SRC.

\*\*RR150060 was withdrawn by the applicant after the meeting of the SRC but before the PIC meeting.

---

## Product Development Research Award Recommendations –

The PIC unanimously recommends approval of two product development grant proposals totaling \$8,500,011. The recommended grant proposals were submitted in response to New Company Product Development Awards and Established Company Product Development Awards Request for Applications. The Product Development Review Council (PDRC) recommended three applications to the PIC; however, the PIC only recommended two to the Oversight Committee. The PDRC provided the prioritized list of recommendations for the product development awards to the presiding officers on April 21, 2015.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these product development proposals met the following CPRIT funding priorities:

- could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;
- are interdisciplinary or interinstitutional (the PIC chose this factor for Established Company Awards);
- are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- have a demonstrable economic development benefit to this state;
- expedite innovation and product development, attract, create, or expand private sector entities that will drive a substantial increase in high-quality jobs, and increase higher education applied science or technology research capabilities; and
- address the goals of the Texas Cancer Plan.

### Product Development Research Grant Award Recommendations

Rank	Application ID	Company Name	Project	Requested Budget	Overall Score
1	DP150019	Vermillion, Inc.	Development and Validation of a Second-Generation Multivariate Test for Use in Assessing Risk of Ovarian Mass Malignancy	\$7,533,011	2.4
2	DP150005	Rosellini Scientific, Inc.	Wireless Neuro-modulation Treatment for Bladder Dysfunction Secondary to Cancer	\$967,000	2.9

Rank	Application ID	Company Name	Project	Requested Budget	Overall Score
3	DP150042*	Aradigm Corp.	Development of AERx Pure Nicotine Inhaler	\$5,330,000	3.0

\* DP150042 was not recommended by the PIC.

### Prevention Award Recommendations –

The PIC unanimously recommends approval of 11 prevention grant proposals totaling \$20,619,413. The recommended grant proposals were submitted in response to Evidence-Based Cancer Prevention Services-Colorectal Cancer Prevention Coalition, Competitive Continuation/Expansion-Evidence-Based Cancer Prevention Services, and Evidence-Based Cancer Prevention Services Request for Applications. The PIC followed the recommendations made by the Prevention Review Council (PRC). The PRC provided the prioritized list of recommendations for the product development awards to the presiding officers on April 21, 2015.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these product development proposals met the following CPRIT funding priorities:

- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
- address federal or other major research sponsors' priorities in emerging scientific or technology fields in the area of cancer prevention or cures for cancer;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- have a demonstrable economic development benefit to this state; and
- address the goals of the Texas Cancer Plan.

### Prevention Grant Award Recommendations

App ID	Mech.	Application Title	Organization	Score	Rank Order Score	Recommended funding
PP150061	EBP-CRC	The C-SPAN Coalition: Colorectal Screening and Patient Navigation	The University of Texas Southwestern Medical Center	2.3	1	\$ 4,800,000*
PP150079	EBP	STOP HCC – Evidence-Based Hepatocellular	The University of Texas Health	2.3	2	\$ 1,488,294

App ID	Mech.	Application Title	Organization	Score	Rank Order Score	Recommended funding
		Cancer Prevention Targeting Hepatitis C Virus Infection	Science Center at San Antonio			
PP150071	EBP	FluFIT on the Frontera: Increasing Colorectal Cancer Screening on the Texas-Mexico Border	Val Verde Regional Medical Center	2.6	3	\$ 1,500,000
PP150053	CCE-EBP	BSPAN3: Breast Screening and Patient Navigation for Rural and Underserved Women across North Texas	The University of Texas Southwestern Medical Center	2.9	4	\$ 1,499,993
PP150054**	EBP-CRC	Alliance for Colorectal Cancer Testing (ACT) in Southeast Texas	The University of Texas M. D. Anderson Cancer Center	2.9	4 (rank ordered without Dr. Brownson)	\$ 2,588,774
PP150077	EBP	Media-Rich Mobile Dissemination of a Dysphagia Prevention Program for Head and Neck Cancer Patients during Radiation	The University of Texas M. D. Anderson Cancer Center	2.9	6	\$ 1,263,342
PP150086	CCE-EBP	Access to Breast and Cervical Care for West Texas (West/Central Texas)(ABCC4WT)	Angelo State University	3.9	7	\$ 1,480,898

App ID	Mech.	Application Title	Organization	Score	Rank Order Score	Recommended funding
PP150080	CCE-EBP	Empower Her To Care Expansion: Increasing Access to Breast Cancer Screening and the Continuum of Care for Underserved Texas Women	The Rose	4.1	8	\$ 1,500,000
PP150078	EBP	Cada Paso del Camino: Outreach, Education, Screening, Health Insurance Navigation, and Linkage to Treatment for Breast, Cervical, and Colorectal Cancers	MHP, Inc. Promoviendo Vidas Saludables	4.5	9	\$ 1,498,337
PP150064	CCE-EBP	University Health System Evidence-Based Colorectal Cancer Prevention Screening Program	University Health System	4.5	10	\$ 1,499,775
PP150089	CCE-EBP	Increasing Breast and Cervical Cancer Screening and Diagnostic Rates in Rural, Frontier, and Border Counties for Uninsured, Underserved Women	Texas AgriLife Extension Service	4.7	11	\$ 1,500,000

\* reduce grant to \$4,800,000. Due to this being the initial coalition grant (largest grant ever awarded) and to efficiencies to be achieved with current grant that has a CRC focus.

---

\*\* PRC noted concerns about ensuring navigation for follow-up and treatment. Per RFA, access to follow-up and treatment must be ensured. PRC recommends grantee be expected to track all abnormal; providing outcomes in routine reports.

Recommendations 7 through 11 were made by the PRC based on several factors including geographic distribution and cancer type.